CRYOPORT, INC. Debt Securities, Available-for-sale
CRYOPORT, INC. (CYRX) had Debt Securities, Available-for-sale of $359.53 million as of 2022-03-31, per its 10-Q filed 2022-05-05.
Discontinued › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2022-05-05
- 2022-03-31: Debt Securities, Available-for-sale $359.53M.
- 2021-12-31: Debt Securities, Available-for-sale $379.69K; Debt Securities, Available-for-sale as first filed $379.69M.
- 2021-09-30: Debt Securities, Available-for-sale $195.74M.
- 2021-06-30: Debt Securities, Available-for-sale $229.13M.
| Period end | Debt Securities, Available-for-sale | Debt Securities, Available-for-sale as first filed |
|---|---|---|
| 2022-03-31 | $359.53M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $379.69K 10-Q · filed 2022-05-05 | $379.69M 10-K · filed 2022-02-28 |
| 2021-09-30 | $195.74M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $229.13M 10-Q · filed 2021-08-06 | |
| 2021-03-31 | $234.58M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $23.31M 10-K · filed 2022-02-28 | |
| 2020-09-30 | $26.43M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $149.51M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $32.68M 10-Q · filed 2020-05-08 | |
| 2019-12-31 | $21.09M 10-K · filed 2021-03-01 | $21.09M 10-K · filed 2020-03-10 |
| 2019-09-30 | $23.09M 10-Q · filed 2019-11-12 | |
| 2018-12-31 | $7.93M 10-K · filed 2020-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |